Emcure Pharma Q2 FY26 Earnings Results: Profit Rises 25% to ₹251 Crore on Strong Domestic and Export Sales

Emcure Pharmaceuticals reported a 25% jump in Q2 profit, reaching ₹251 crore, compared to ₹202 crore in the same quarter last year. The rise came mainly from strong sales in both Indian and international markets.

Revenue Performance

The company’s revenue from operations increased to ₹2,270 crore in the September quarter, up from ₹2,002 crore a year earlier.

Strategic Focus and Partnerships

CEO and MD Satish Mehta said Emcure continues to strengthen its product portfolio across key markets through in-licensing and in-house innovations.

He also highlighted that the company’s partnership with Novo Nordisk gives it an early entry into the rapidly growing obesity treatment market, helping Emcure shape future demand.

Read More: Dividends, Buybacks, and Stock Splits This Week (Nov 10–14, 2025): Infosys, Power Grid, NALCO, and More.

Emcure Pharmaceuticals Share Price Movement

Emcure Pharmaceuticals share price (NSE: EMCURE) closed at ₹1,367.00, down 4.18% for the day, after trading between ₹1,362.40 and ₹1,453.80. The stock opened at ₹1,430.20 and now sits well above its 52-week low of ₹889.00, but below its 52-week high of ₹1,519.90. Emcure has a market cap of ₹25,910 crore, a P/E ratio of 34.74, and a dividend yield of 0.22%. For the quarter, the company has declared a dividend of ₹0.75 per share.

Conclusion

Emcure Pharma delivered solid growth in Q2 with higher profits and rising revenue. Its focus on expanding its portfolio, backed by strategic partnerships, positions the company well for future opportunities, especially in fast-growing therapy areas.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.